FibroGen, Inc.的动态

GenFleet has finished the dosing of the first patient with GFH375/VS-7375, a potent and selective oral KRAS G12D (ON/OFF) inhibitor, as part of a Phase I/II clinical trial in China. The Phase I part of the trial aims to evaluate the safety and efficacy of the therapy in patients with advanced KRAS G12D mutant solid tumours. This oral inhibitor has shown promise in preclinical studies, demonstrating the potential to address a variety of solid tumours, including those with brain metastases. The ongoing Phase I trial will involve approximately 20 hospitals across China and establish the recommended Phase II dose. Subsequently, Phase II will further investigate GFH375/VS-7375's efficacy and safety in treating advanced solid tumours such as colorectal cancer, pancreatic ductal adenocarcinoma, and non-small cell lung cancer. Please click the link for its full version: https://lnkd.in/gB54xgVJ

#transcript Joe Ferra CEO of Elevation Oncology highlights the unmet needs in gastric cancer & the potential of targeting Claudins, proteins involved in cell adhesion. The current competitive landscape of antibody drug conjugates ADCs confirms the promise of a targeted therapy that delivers a cytotoxic drug directly to cancer cells. Targeting Claudin 18.2 with an ADC approach offers an opportunity to treat a broader range of tumors expressing a lower level of Claudin 18.2 than those currently treated by CAR-T therapy. This approach is being investigated as a single-agent drug with promise for use in combination for gastric cancer, pancreatic cancer & esophageal cancer. ElevationOncology.com https://lnkd.in/dpGYCKGK

BiVictriX Therapeutics plc (AIM:BVX, OTC:BVTXF) has reported positive initial results from preclinical testing of its lead solid tumour treatment, BVX002, targeting ovarian cancer. BVX002 is?a bispecific antibody-drug conjugate (Bi-Cygni ADC), a targeted cancer treatment that combines two antibodies to specifically attack cancer cells while carrying a powerful drug to kill them. This approach helps focus treatment on cancer cells, reducing damage to healthy cells and lowering side effects. In a mouse model, the drug showed?tumour growth reductions between 78.3% and over 100%. Shrinkage of up to 63.1% was observed at mid and high doses. The drug was administered weekly over four doses and was well tolerated even at the highest levels, with no major side effects. More at #Proactive #ProactiveInvestors https://ow.ly/frjA105I699

Last month, Altamira Therapeutics filed a second provisional patent application for OligoPhore? nanoparticles targeting different #KRAS mutations in cancer treatment. Although the role of KRAS mutations in cancer has been known for decades, they have remained a challenging target for therapeutic interventions. KRAS was long considered undruggable, in part, because of the lack of obvious binding sites. Only recently, the FDA approved the first two treatments for KRAS-driven cancer: sotorasib and adagrasib, two small molecule inhibitors of G12C-mutated KRAS for the treatment of NSCLC. We look forward to advancing our AM-401 program to provide clinicians and patients with a comprehensive treatment option for KRAS-driven cancers: https://bit.ly/3HwrVmw #Science #RNATherapeutics #siRNA #mRNA

HER2-Negative Breast Cancer Pipeline Insights, Treatment Drugs, Emerging Therapies and Companies 2024: DelveInsight’s,?“HER2-Negative Breast Cancer Pipeline Insight 2024”?report provides comprehensive insights about?70+ companies and 75+ pipeline drugs?in HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics … Continue reading → #PharmaceuticalsBiotech

This Nature article explains the promise of Claudin-1 as a target in oncology! Nice-read of the day!

A very interesting read, explaining the science behind some of Alentis Therapeutics' early phase trials, making headway in the research of CLDN1 targeted-therapies. 'CLDN1 overexpression is almost universal in patients with advanced Head and Neck Squamous Cell Carcinoma (HNSCC)' 'HNSCC is the seventh most common cancer globally, with around 890,000 new cases and 450,000 deaths annually. In its advanced stages, there are very few treatment options.' #HNSCC #AlentisTherapeutics #CLDN1

Antibody drug conjugates #ADCs are not ready for prime time in non-small cell lung cancer #NSCLC, which is particularly challenging given its resistance to chemotherapy and radiation. A major challenge in developing ADCs for NSCLC is that unlike many cancers, lung cancer isn’t typically treated with antibody therapies, say analysts. But that’s not to say they’re totally obsolete.?Read my latest about the drugs making inroads in this field: https://lnkd.in/gzat2VPV #oncology #lungcancer

Metastatic Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers: DelveInsight’s,?“Metastatic Breast Cancer Pipeline Insight”?report provides comprehensive insights about 100+ companies and 100+ pipeline drugs?in Metastatic Breast Cancer pipeline landscape. It covers the Metastatic Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic … Continue reading → #PharmaceuticalsBiotech

??Advancing ovarian cancer research: Our customer publication highlights a significant step forward in High-grade serous ovarian cancer (HGSOC) diagnosis and therapy. Leveraging our passive microfluidic platform with 3D cancer organoids, this study offers a standardized, sample-efficient, and versatile approach for exploring novel therapeutic strategies. ?? Optimizing passive flow conditions enhances cancer organoid growth, minimizing disruption to the extracellular matrix. Results demonstrate accelerated drug response rates under passive flow, with lower IC50 values compared to static conditions. FITC-labeled paclitaxel showcases improved ECM penetration, leading to a more efficient drug-induced organoid demise. ???? These important findings underscore the significance of cancer organoids as valuable tools for ex vivo drug testing, replicating patient responses in clinical settings. This study, utilizing patient-derived organoids, paves the way for enhanced drug screening protocols in ovarian cancer research. #HGSOC #CancerResearch #Oncology #Organonachip ??Read the full publication here: https://lnkd.in/erks2Dvh